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ABSTRACT 
Neuroendocrine tumours (NET) often present at a metastatic stage, which 
diminishes the possibility for curative surgery. Peptide receptor radiotherapy 
(PRRT) with 177Lu-DOTATATE targets somatostatin receptors, which are 
overexpressed on NET cells. PRRT results in symptom relief and often tumour 
control of NETs, but rarely cure. Tumour response is variable and renal and 
haematological toxicity are dose-limiting side effects. 
In metastatic small intestinal NET (SI-NET) hepatic metastases are often a 
clinical problem. Several treatment options exist and radioembolization (RE) 
of the liver is a recently introduced therapy. Diffusion weighted MRI (DWI) is 
a new imaging technique reflecting the microenvironment of tumours and is 
maybe useful for treatment response evaluation. 
Aims of the thesis project were to identify predictive factors for response and 
long-term outcome after PRRT, and investigate a possibility for 
radiosensitization. Further, RE was compared to hepatic artery embolization 
(HAE) for SI-NET hepatic metastases, and the utility of DWI as a predictor for 
morphologic treatment response was investigated. 
A retrospective study of 51 NET patients treated with 177Lu-DOTATATE 
revealed an objective response rate of 13%, however most patients responded 
with a halted tumour growth. High tumour proliferation rate, but not diagnosis, 
was associated with shorter survival. Overall long-term toxicity was low. The 
absorbed tumour dose varied considerably within and between patients, but the 
median absorbed tumour dose was correlated with tumour shrinkage.  
In a retrospective study on stage IV SI-NET, patients with low somatostatin 
receptor 2 (SSTR2) expression did not have an inferior outcome after PRRT. 
 In contrast, a tendency was found towards both higher activity uptake after 
PRRT and longer survival. 
In an experimental animal study, the NAMPT inhibitor GMX1778 enhanced 
the efficacy of 177Lu-DOTATATE and almost eradicated all tumours. 
In a clinical prospective study on SI-NET hepatic metastases, HAE resulted in 
earlier tumour shrinkage than RE, and the response at 3 months was correlated 
with DWI after 1 month. A low baseline apparent diffusion was correlated with 
a larger tumour shrinkage after 6 months. 
In conclusion, tumour grade can predict long-term outcome after PRRT in 
metastatic NET and tumour dosimetry can be useful for response prediction. 
Low SSTR2 expression should not exclude patients from PRRT. GMX1778 
might be used as a radiosensitizer in PRRT for SI-NET. DWI can be useful for 
prediction and early evaluation of treatment response after RE and HAE for 
liver metastasized SI-NET. 
Keywords: neuroendocrine tumour, peptide receptor radionuclide therapy, 
somatostatin receptor 2 expression, radiosensitization, radioembolization, 
diffusion weighted imaging 
SAMMANFATTNING PÅ SVENSKA 
Neuroendokrina cancertumörer (NET) utgår från celler med förmåga att 
utsöndra ämnen, som kan ge hormonellt orsakade tillstånd och symptom såsom 
diarré, värmevallningar, magsår och blodsockersvängningar. När tumörerna 
har spridit sig till lymfkörtlar och lever, går sjukdomen inte längre att bota med 
kirurgi. Receptor-medierad strålbehandling (PRRT) med den radioaktiva 
isotopen Lutetium-177 (177Lu-DOTATATE) riktar sig mot somatostatin-
receptorer (SSTR), som finns på cellytan av de flesta NET. Tumörerna är 
generellt långsamväxande, vilket gör att strålbehandling ofta har begränsad 
effekt, men PRRT har visats förlänga överlevnaden hos patienter med spridd 
NET. Behandlingen, som ges intra-venöst, ger symptomlindring och bromsar 
tumörtillväxten, men leder sällan till bot. Behandlingseffekten av PRRT 
varierar och man vet fortfarande ganska lite om vilka faktorer som påverkar 
utfallet. PRRT ger också dosberoende biverkningar i form av försämrad 
funktion av njurar och benmärg p.g.a. att även normalvävnad bestrålas. 
Vid NET med ursprung från tunntarmen (SI-NET) utgör levermetastaserna 
ofta ett kliniskt bekymmer, eftersom de är många och kan bli mycket stora, och 
därigenom orsakar de svåra hormonella symptom. Behandling riktad specifikt 
mot levern är att föredra, eftersom sådan inte påverkar njur- och 
benmärgsfunktionen, som systembehandlingar kan göra. Levertumörer får sitt 
blod huvudsakligen via lever-pulsådern och genom att ge behandling direkt i 
denna får man inte så mycket påverkan på den friska levervävnaden, som 
huvudsakligen försörjs vi porta-venen. Radioembolisering (RE) via lever-
pulsådern är en ny strålbehandling med mikrosfärer innehållande den 
radioaktiva isotopen Yttrium-90 och utövar effekt genom stålning. 
Leverartärembolisering (HAE) är en beprövad metod, som ger infarkt i 
levertumörerna genom att blodflödet i lever-pulsådern stängs av med 
insprutade partiklar. Behandlingsutvärdering görs vanligen med 
datortomografi, men magnetkamera med diffusionsviktade bilder (DWI) är en 
ny avbildningsmetod, som avspeglar mikromiljön i tumörerna. 
Syftet med delstudie I-II var att hitta faktorer som skulle kunna förutsäga 
behandlingssvar och långtidsresultat hos 51 patienter, som erhöll PRRT 2006 
till 2011 på Sahlgrenska Universitetssjukhuset. Syftet med delstudie III var att 
undersöka om SI-NET kunde göras mer känsliga för PRRT genom 
kombinationsbehandling med GMX1778. Syftet med delstudie IV var att 
jämföra RE med HAE och studera om DWI kan användas för tidig 
behandlingsutvärdering och för att förutsäga behandlingssvar. 
 I första delstudien såg vi att få tumörer krympte signifikant av PRRT men de 
flesta tumörers tillväxt avstannade. En hög tillväxthastighet (proliferation) i 
tumörcellerna ledde till snabbt återfall och kortare överlevnad för dessa 
patienter.  Långtidsbiverkningarna av PRRT var få. Den absorberade 
stråldosen i tumörerna varierade kraftigt mellan tumörer inom och mellan 
patienter. Vi kunde påvisa ett samband mellan absorberad median-tumördos 
och storleksminskning av tumörerna. 
I den andra delstudien undersöktes SI-NET-tumörer mikroskopiskt, varpå vi 
fann att de flesta tumörer uttryckte en hög nivå SSTR subtyp 2. Patienter med 
tumörer med lågt SSTR2-uttryck hade en tendens till högre upptag av 
radioaktivitet vid PRRT, vilket var överraskande. Dessutom hade de en 
tendens till längre överlevnad, vilket var motsatt vår hypotes. 
Den tredje delstudien var en experimentell modell med human SI-NET, där 
PRRT-behandlade möss även fick GMX1778, som hämmar ett enzym i 
processen att återskapa NAD+. NAD+ är ett ko-enzym som är centralt för 
cellers energitillverkning och det förbrukas vid strålskada. Kombinations-
behandlingen förstärkte effekten av PRRT och resulterade i att tumörerna 
nästan försvann helt, utan någon annan effekt på mössen. 
Den fjärde delstudien var en prospektiv jämförande behandlingsstudie på 
patienter med levermetastaser från SI-NET. HAE gav tumörkrympning 
tidigare än RE, men efter 6 månader sågs inte längre någon säker skillnad 
mellan behandlingarna. Ökning av diffusion mätt med DWI en månad efter 
behandling korrelerade med tumörkrympning vid 3 månader. Lågt 
diffusionsvärde innan behandling korrelerade med tumörkrympning vid 6 
månader. 
Slutsatser som kan dras är att PRRT är en väl tolererad behandling, där 
tumörens proliferationsgrad korrelerar med överlevnad. Tumördosimetri kan 
vara användbar för att förutsäga behandlingssvar. Lågt SSTR2-uttryck bör inte 
exkludera patienter från PRRT. GMX1778 kan möjligen användas för 
radiosensibilisering vid PRRT för SI-NET. DWI kan vara användbar för att 
förutsäga och tidigt utvärdera behandlingssvar efter RE och HAE vid 
levermetastaserad SI-NET. 
THESIS AT A GLANCE 
 
Paper Questions Methods Results Conclusions 
I Can predictive 
factors be identified 
for long-term 
outcome or toxicity 
after PRRT (177Lu-
DOTATATE)? 
Is the absorbed 
tumour dose 
predictive of 
morphological 
tumour response? 
Retrospective 
descriptive study on 
our first 51 patients 
treated with 177Lu-
DOTATATE. RECIST 
and biomarker 
evaluation. Long-term 
follow-up with PFS and 
OS. Tumour dosimetry 
using planar 
scintigraphy and 
SPECT after treatment. 
The PFS and OS was 
similar regardless of 
NETdiagnosis, but patients 
with G3 tumours had a 
shorter PFS and OS than 
those with G1 and G2 
tumours. Side effects were 
few. In a heterogeneous 
NET cohort a correlation 
was found between median 
absorbed tumour dose and 
tumour shrinkage. 
For evaluation of metastatic 
NET after 177Lu-
DOTATATE, Ki-67 is a 
stronger predictive marker 
for long-term outcome than 
tumour origin. Tumour 
dosimetry is feasible and 
seems to correlate with 
tumour shrinkage, however 
large variations were seen 
within and among patients. 
II Can low SSTR2 
expression predict a 
worse outcome after 
177Lu-DOTATATE? 
Is the radioactivity 
uptake lower in 
tumours with low 
SSTR2 expression? 
IHC analysis of TMA 
block for SSTR2 and 
Ki-67 compared with 
OS in SI-NET patients 
treated with 177Lu-
DOTATATE. 
Measurement of 
activity concentration 
in SPECT 24h after 
PRRT. 
SI-NET patients with low 
expression of SSTR2 did 
not have a shorter OS after 
PRRT, compared to 
patients with high 
expressing tumours. Nor 
did they have a lower 
radioactivity uptake at 24h 
SPECT. 
The expression of SSTR2 
cannot predict long-term 
outcome after 177Lu-
DOTATATE for 
metastasized SI-NET, 
hence patients with low 
expression should not be 
excluded from PRRT. 
III Can NAMPT 
inhibitor GMX1778 
be used as a 
radiosensitizer in SI-
NET? 
Experimental study 
with nude mice 
xenografted with SI-
NET followed for 17 
weeks. Measurement of 
tumour size, time to 
tumour progression. 
Combining a low dose of 
GMX1778 with a low dose 
of 177Lu-DOTATATE 
resulted in substantially 
reduced tumour volumes 
and a prolonged time to 
tumour progression. 
GMX1778 enhances the 
tumour reducing effect of 
177Lu-DOTATATE and 
prolongs time to tumour 
progression. Hence, 
GMX1778 can be used as a 
radiosensitizer for PRRT.  
IV Is there a difference 
in treatment outcome 
after HAE and RE? 
Can DWI be an early 
predictor of treatment 
response in SI-NET 
hepatic metastases? 
Prospective study 
randomizing to HAE or 
RE with 90Y. RECIST 
and biomarker 
evaluation. Baseline 
and 1-month DWI 
compared with MRI 3 
and 6 months. 
Patients treated with HAE 
had initially a better tumour 
response, but at 6 months 
the response was similar 
for both treatments. A low 
baseline and high increase 
of 1-month DWI correlated 
with pronounced tumour 
shrinkage. 
At 6 months, the response 
is similar after HAE and 
RE. Early measurement of 
the apparent diffusion 
coefficient (ADC) seems to 
predict tumour response. 
PFS=progression-free survival, OS=overall survival, NET=neuroendocrine tumour, PRRT=peptide receptor 
radionuclide therapy, SSTR2=somatostatin receptor type 3, IHC=immunohistochemical, SI-NET=small intestinal 
NET, HAE=hepatic artery embolization, RE=radioembolization, DWI=diffusion weighted imaging 
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INTRODUCTION AND 
BACKGROUND 
This doctoral thesis focuses on outcome after receptor-mediated radionuclide 
therapy of neuroendocrine tumours (NETs), especially small intestinal and 
other gastro-entero-pancreatic NETs (SI-NETs and GEP-NETs), and explores 
radiosensitization as a way to increase the efficacy of the treatment. It also 
compares radioembolization to traditional bland embolization as a treatment 
for SI-NET hepatic metastases and investigates diffusion weighted MRI as an 
evaluation method. 
 
NEUROENDOCRINE TUMOURS 
Neuroendocrine tumours (NETs) arise from neuroendocrine cells situated in 
various tissues in the body (1). The most common types are broncho-
pulmonary and gastro-entero-pancreatic tumours (GEP-NETs) (2). Clinical 
presentation depends on the cell type and site of the primary tumour, and 
whether they are functioning tumours, i.e. hormone producing with specific 
hormonal symptoms. Among metastasized GEP-NETs, SI-NET is the most 
common diagnosis, characterized by its overproduction of serotonin. A large 
tumour burden can cause the classical carcinoid syndrome with diarrhoea, 
cutaneous flushing and abdominal pain as cardinal symptoms, together with 
right-sided heart valve dysfunction. The neuroendocrine pancreatic tumours 
(pan-NETs) are often non-functioning, which leads to a late clinical 
presentation with mass effect, such as diffuse abdominal pain, as the 
predominant symptom. The late detection can also result in a higher stage with 
distant metastases at diagnosis. The functioning pan-NETs cause symptoms at 
an earlier stage, e.g. hypoglycaemia (insulinomas) and recurrent peptic ulcers 
(gastrinomas). 
The incidence of NETs is about 2.5-5/100000, but the prevalence is much 
higher due to their mostly slow growing nature, which gives the patients a 
fairly long survival (2-5). The incidence has increased substantially during the 
last decades, as described in the SEER database (6). This is probably due to 
more frequent and more sensitive radiological and endoscopical examinations, 
as well as refined histopathology. 
Targeted radiotherapy of metastatic NET 
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Diagnosis 
The slow progression of NETs leads to an indolent course and delayed 
diagnosis at an already advanced stage. Almost half of all SI-NETs are 
diagnosed in an acute setting due to intestinal obstruction and impaired 
circulation. This is caused by primary tumours or mesenteric lymph node 
metastases together with the typical desmoplastic reaction often associated 
with SI-NETs (7). 
When a suspicion of neuroendocrine tumour is raised, biochemical screening 
should be performed together with imaging. This includes the general NET 
marker chromogranin A (CgA), together with site-specific hormones or their 
metabolites, e.g. dU-5-HIAA in SI-NETs (8). 
Detailed staging is necessary for proper management and is reached by the 
combination of computed tomography (CT) or magnetic resonance imaging 
(MRI) and functional imaging of somatostatin receptors (SSTR) (see SSTR 
chapter). CT and MRI typically show contrast enhancement due to the rich 
vascularization of NET.  
Another useful diagnostic tool, especially in upper gastro-intestinal  and pan-
NETs, is endoscopic ultrasound (EUS) (9). In hereditary syndromes with 
multiple tumours, the lesions are sometimes very small and can be difficult to 
localize with CT or MRI. EUS is then a more sensitive imaging modality, and 
does not expose the patient to radiation, which is advantageous when repeated 
exams are needed. Furthermore, the EUS technique enables obtaining a biopsy 
with good precision (10). 
The definite diagnosis is established with a tumour biopsy, which is 
immunohistochemically (IHC) stained for CgA, synaptophysin and relevant 
hormones (Fig. 1). Proliferation rate for grading is revealed by the mitotic 
count and/or the Ki-67 index, using the MIB1 antibody (11). A tumour biopsy 
cannot always be obtained preoperatively. Then imaging and convincing 
biomarkers can be enough for the decision to operate. 
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Figure 1. Micrographs of SI-NET. A. Histopathological staining with 
hematoxylin-eosin. B. Immunohistochemical (IHC) staining for 
Chromogranin A visualizes neuroendocrine cells, mainly located in the 
tumour. C. IHC staining for Ki-67 with the antibody MIB1 reveals tumour 
proliferation rate. 
 
Classification, staging and grading 
NETs are at diagnosis classified by two parameters: stage and grade. These are 
important prognostical factors for long-term outcome in NETs (6, 12, 13). The 
tumour-node-metastasis (TNM) classification is used, and stage is of great 
importance for planning of treatment for the patient (14). T is determined by 
the size and infiltration depth of the primary tumour, N and M are determined 
by the presence of regional lymph node and distant metastases, respectively. 
The anatomical extent of the disease is the classified into stage I-IV, where 
stages III and IV are mainly defined by the presence of lymph node and distant 
metastases. 
Grade Mitotic count per 10 HPF Ki-67 index* (%) 
G1 < 2 < 3 
G2 2 - 20 3 - 20 
G3 > 20 > 20 
 
Table 1. Grading of gastroenteropancreatic neuroendocrine neoplasias. HPF = 
high-power fields, * MIB1 antibody: per cent of 500-2000 cells (15) 
A B C 
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The European Neuroendocrine Tumour Society (ENETS) has developed a 
histopathological grading system with three categories (G1, G2, G3), based on 
Ki-67 index and mitotic count (Table 1) (15). 
Most common are G1 and G2 tumours, which have a significantly better 
prognosis than G3. However, G3 tumours are a heterogeneous group, and they 
are often divided in G3 NET (lower Ki-67 range) and G3 NEC 
(neuroendocrine carcinoma) (Ki-67>55%). G3 NETs are treated similarly to 
G2 tumours, but G3 NECs have a significantly worse prognosis, often 
necessitating other treatments than G1, G2 and G3 NETs. In newer 
terminology all G1-G3 tumours are referred to as neuroendocrine neoplasias 
(NEN), which include both NETs and NECs.  
 
TREATMENT OF GEP-NETS 
GEP-NETs constitute a very heterogeneous group of tumours, from small 
gastric and rectal NETs to metastasized, fast growing G3 NECs. In a 
nationwide Swedish register study including all kinds of NENs from all sites, 
23% were metastatic. Small intestinal and pancreatohepatobiliary (mostly 
pancreatic) NENs carried the highest proportion of metastases, 41% and 
58%, respectively. Appendiceal and rectal NENs were rarely metastastic, 3% 
and 13%, respectively. Colon and gastric NENs had metastases in 18% and 
31%, respectively (16). Obviously, the treatments are as diverse as the 
tumours. Here, mainly treatments of G1 and G2 SI-NETs and pan-NETs are 
discussed. 
 
Surgical treatment 
Incidentally discovered GEP-NETs, when the disease is loco-regional and 
before start of hormonal symptoms, are treated with a curative intent. In SI-
NETs, a bowel resection with regional lymphadenectomy is usually performed, 
resulting in an excellent prognosis with a 5-year survival of 100% for stage I 
and II and 97% for stage III disease (17-19). In stage IV disease (distant 
metastases present) resection of the primary tumour and lymph nodes are 
usually resected, however the long-term benefit of this has been questioned 
(20). In pan-NETs, the stage and grade are important prognostic factors for 
long-term outcome (21-24), and are also used as a guide to timing of surgery. 
For non-functional, small G1 tumours an active surveillance approach could 
be applied, with repeated radiological follow-up examinations. For larger (> 2 
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cm) or G2 tumours resection is recommended (25). Furthermore, the 
localization of the tumour is of great importance, since the surgical procedures 
have different side effects and complication rates, depending on if the caput 
(Whipple’s procedure) or the cauda (laparoscopic tail resection) is resected. A 
functioning tumour most often leads to a pancreatic resection up-front, due to 
the hormonal symptoms. 
 
Systemic treatment 
Since NETs are often metastasized when symptoms occur, the treatment is 
commonly multimodal with a palliative intent. Beside somatostatin receptor 
mediated therapies (see SSTR chapter), chemotherapy, oncogenic pathway 
inhibitors and interferon-a have been used. 
In G3 tumours, chemotherapy is an important part of the multimodal approach 
for localized disease and the mainstay of treatment in advanced or metastatic 
disease (26). Generally, platinum-based chemotherapy is used in combination 
with etoposide. For G2 NETs in higher range and G3 tumours in the lower 
range temozolamide and capecitabine could be considered (26). 
In recent years, molecular targeted therapies have been introduced for 
treatment of NETs. These therapies include the mTOR inhibitor everolimus 
and the tyrosine kinase inhibitor sunitinib. Everolimus has been compared to 
placebo in a large randomized controlled study on advanced G1-G2 NETs, 
showing a prolonged progression-free survival (PFS) in favour of everolimus 
(11 versus 3.9 months) (27). Sunitinib has been investigated for well-
differentiated (G1-G2) pan-NETs in another placebo-controlled study. The 
study was discontinued early after 22 months due to more adverse events and 
deaths in the placebo group as well as a difference in PFS favouring sunitinib 
(11.4 versus 5.5 months) (28). Indeed, these are convincing results, but in both 
of these studies the control groups were left with only placebo treatment, 
something that rarely is the case in the clinic. 
 
TREATMENT OF HEPATIC METASTASES 
The liver is the main site for distant metastases in GEP-NETs, and the presence 
of hepatic metastases influences the prognosis (29). These metastases can be 
large and extensive, and they are the main source for hormonal symptoms. In 
SI-NETs, secretory products from the primary tumours and regional lymph 
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nodes follow the portal vein blood and are metabolized in the liver, while 
tumour products from hepatic metastases are secreted directly into the systemic 
circulation, giving rise to the carcinoid syndrome. A number of treatment 
alternatives have been introduced for hepatic metastases. 
 
Surgical resection 
The primary tumour and regional lymph node metastases can often be resected 
radically. Surgery is also the treatment of choice for G1 and G2 hepatic NET 
metastases if a complete resection of liver metastases could be performed 
safely (29-31). In this setting, surgical intervention has in retrospective studies 
shown a survival benefit compared with less aggressive (non-
surgical/pharmacological) treatment (32, 33). For selected patients, liver 
transplantation can be a treatment option (34, 35). 
 
Non-surgical therapy 
In most cases, the hepatic metastases are widely spread or the patient have co-
morbidities making surgical resection unsuitable. In patients with 
predominantly hepatic tumour burden, a liver-directed regional treatment is a 
preferable alternative, since systemic adverse reactions, e.g. haematological 
toxicity and other side effects from chemotherapy, oncogenic pathway 
inhibitors and interferon-a,  can be avoided.  These non-surgical treatments are 
considered palliative and include ablation and trans-arterial embolization of 
hepatic metastases. They result in symptomatic relief and often tumour 
regression, but no differences between treatments regarding long-term 
outcome have been confirmed in meta-analyses (31, 36, 37). Factors affecting 
the choice of method mainly regard severity of disease and distribution of 
metastases. 
 
Ablation 
Ablation of hepatic metastases is accomplished by radiofrequency, microwave 
or laser techniques. All techniques induce hyperthermia and can be performed 
percutaneously or intra-operatively with sonographic guidance. The treatment 
has a high tolerability and side effects are rare and mainly related to the 
electrode placement (38, 39). In SI-NETs, ablation can lead to decreased 
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biomarkers and delayed tumour progression, but OS is probably not prolonged 
(40). 
Ablative procedures necessitate treatment of metastases individually, which 
limits the number of metastases that can be treated at one occasion. Not all 
metastases can be visualized on the pre-therapeutic ultrasound, and for 
technical reasons, larger metastases cannot be treated. Further, metastases 
located adjacent to the diaphragm, heart or bile ducts are unsuitable for 
percutaneous treatment, due to the heat dispersion from the ablative procedure. 
In metastases close to larger vessels it is difficult to achieve hyperthermia due 
to the cooling effect of the blood flow. 
 
Embolization 
Neuroendocrine tumours are highly vascularized with their main blood supply 
from the hepatic artery, while the liver parenchyma is perfused mainly by the 
portal vein. By embolization via the hepatic artery a certain degree of tumour 
specificity of the treatment can be achieved (41). Trans-arterial embolization 
can be performed using three different strategies (Fig. 2). The side effects differ 
between treatments and vary depending on their different way of acting. 
Figure 2. Embolization of liver. Via a catheter inserted in the right 
femoral artery, the right or left hepatic artery branches (in HAE or 
HACE) or the common hepatic artery (in RE) are reached, where the 
embolization treatment is deposited. Normal liver tissue is perfused 
mainly via portal vein, and is spared from the embolization treatment. 
Illustration from American Cancer Society. 
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Hepatic artery embolization (HAE), or bland embolization, using polyvinyl 
alcohol (PVA) particles or gelatine foam, aims to completely block the 
circulation in the hepatic artery, which induces tumour ischemia and necrosis. 
(42). The treatment is divided into two sessions approximately six weeks apart, 
treating one lobe at a time to avoid serious side effects. Nevertheless, main side 
effects are related to ischemia and include abdominal pain, nausea, fever and 
transiently increased hepatic enzymes. Rarely, hepatic abscesses and 
hepatorenal syndrome are seen (43). 
In hepatic artery chemoembolization (HACE) the procedure is similar, but 
streptozotocin or doxorubicin is added. This gives a regional cytotoxic effect 
to the embolization, but at much higher levels than systemic chemotherapy 
(44). A wider spectrum of side effects is also seen, compared with HAE. 
Radioembolization (RE) is aiming not for ischemia but for a tumour selective 
deposition of radiolabelled microspheres (90Yttrium), hence an internal 
radiotherapy. The particle size is significantly smaller and amounts much less 
than in HAE, which avoids ischemic side effects and the whole liver can be 
treated at once. Common side effects described after RE are abdominal 
discomfort and fatigue for some weeks (45, 46). Usually patients are 
discharged on the day after treatment, in contrast to patients receiving HAE, 
who need median 4 hospital days after treatment (43). 
HAE and HACE often result in reduced biomarkers, symptom relief and 
tumour regression (47), and maybe an improved long-term outcome in 
responding patients (48, 49). Furthermore, RE is described to result in effective 
disease control and improved quality of life (50). 
There are only few studies comparing the different embolization therapies, and 
these are often retrospective, introducing bias. Included patients are often 
heterogeneous regarding tumour origin and grade, which complicates 
evaluation and makes it difficult to draw firm conclusions. For SI-NETs, there 
seems to be no benefit with HACE compared with HAE, but maybe for p-
NETs (51). However, HACE seems to be more toxic than HAE (52). In a small 
retrospective study on both HAE, HACE and RE no differences between PFS 
or overall survival (OS) was seen between the groups (53). 
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SOMATOSTATIN RECEPTORS 
Somatostatin receptors (SSTR) are G-protein coupled receptors that are 
normally expressed in many tissues in the body, including the gastrointestinal 
tract, kidneys, pancreas and nervous system. Five major receptor subtypes are 
identified (1-5) and they are overexpressed in many NET cells. SSTR2 is the 
subtype most commonly overexpressed by GEP-NETs (54, 55). To some 
extent, SSTR1 and SSTR5 are also overexpressed. When the receptor is 
activated by the endogenous ligands somatostatin-14 and -28, an inhibition of 
gastrointestinal motility, endocrine and exocrine secretion via intracellular 
cAMP and Ca2+ connected pathways (56). 
 
Somatostatin analogues 
Octreotide, the first somatostatin analogue (SSA), was synthesized more than 
3 decades ago by the chemist Wilfried Bauer (57). This synthetic peptide has 
an increased inhibitory activity and prolonged duration of action, compared 
with natural somatostatin. It has a high affinity for SSTR2 and moderate 
affinity for SSTR3 and SSTR5, making it ideal in the treatment of GEP-NETs 
(56). Other SSAs have been synthesized, where the most important are 
lanreotide, with similar SSTR affinities as octreotide, and pasireotide, with 
affinity for SSTR5 and SSTR1-3 (58, 59). 
 
Octreotide has been used clinically for many years for its symptom-reducing 
effect on hormone secreting NETs (60). Occasionally, a reduction of tumour 
progression was also seen, and this anti-proliferative effect has been confirmed 
in two large studies with long-acting SSA, PROMID and CLARINET (61, 62), 
where octreotide and lanreotide was compared with placebo. These studies 
showed that PFS was significantly longer for the patients with SSA treatment, 
but no difference in overall survival could be demonstrated. The lack of 
survival benefit was however not unexpected, since placebo treated patients 
were allowed to cross-over to SSA at tumour progression. 
 
Somatostatin receptor mediated imaging 
Somatostatin receptors are also used for diagnosis of NETs. SSTR-positive 
tumours are visualized by imaging using radiolabelled SSA and scintigraphy 
or positron emission tomography (PET).  This type of imaging was first 
performed by using an iodine radionuclide (123I), but soon 111In was established 
as the preferable isotope due to better physical and metabolic properties (63). 
111In is connected via the chelating agent diethylene triamine pentaacetic acid 
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(DTPA) to octreotide, which is readily bound to the SSTR. As 111In emits 
gamma rays, SSTR positive tumours can be visualized by a gamma camera, 
i.e. somatostatin receptor scintigraphy (SRS). 
This technique has been used for many years as an important tool for diagnosis, 
staging and treatment evaluation of NETs. However, the low sensitivity for 
small and certain types of lesions has been an issue for concern. In more recent 
years the positron emitting radionuclide 68Ga has been labelled to somatostatin 
analogues, e.g. 68Ga-DOTATATE, enabling the use of positron emission 
tomography (PET) for visualization. This imaging technique has emerged as a 
more sensitive imaging method (64, 65). It is often combined with a low-
resolution CT (PET/CT) to obtain 3D anatomical images. 
 
Somatostatin receptor mediated therapy 
The radionuclide 111In is mainly a gamma emitter, making it well suitable for 
tumour detection in a gamma camera. Since it also emits high linear energy 
transfer Auger electrons, it was initially investigated for radiotherapeutic use 
in NETs (66, 67). This peptide receptor radionuclide therapy (PRRT) lead to 
symptomatic relief and biomarker decrease, but tumour shrinkage was rarely 
observed. Further, the high activity amounts needed for therapy entailed 
substantial levels of gamma radiation, with radioprotective concerns as a 
consequence.   
Many radionuclides have been theoretically and experimentally investigated 
for their feasibility as radiopharmaceuticals in PRRT (68, 69). The most 
commonly used radionuclide is 131I for therapy of thyroid diseases. For 
somatostatin receptor mediated radiotherapy, 177Lu and 90Y are the most 
frequently used radionuclides, which have appropriate radio-physical 
characteristics for treatment purposes, and are also suitable for industrial 
production (Table 2). 
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 Type of decay Range (max; mm) Half-life (days) 
111In EC, g Short range 2.8 
177Lu ß, g 2 6.7 
90Y ß 11 2.7 
 
Table 2. Physical properties of radionuclides used in PRRT. EC= electron capture 
 
The short range of 177Lu affects tumour cells in close proximity, theoretically 
sparing the normal tissue. 177Lu also emits gamma radiation, which facilitates 
detection and quantification using gamma cameras. The longer range of 90Y 
enables an effective treatment of larger tumours, and possibly compensates for 
uneven distribution of the radioactivity. However, the long range is also a 
disadvantage when treating an abundance of small hepatic metastases 
(diameter <1 mm) (70), and the renal function is more often affected than with 
177Lu (71, 72). Furthermore, its exclusive ß emitting decay complicates post-
injection detection with gamma cameras.  
In order to direct the radionuclide to the tumour, it is bound via a chelator to 
the peptide, which in turn acts as a ligand to the SSTR. Improvement of PRRT 
has included development of new chelating agents as well as peptides.  The 
chelator dodecane tetraacetic acid (DOTA) has superior biodistributive and 
stabilizing characteristics compared with DTPA (73). The binding of the 
radionuclide-ligand complex was improved when introducing the peptide 
octreotate, which has a higher affinity for the SSTR2 (74, 75). 
 
177LU-DOTATATE TREATMENT 
The most commonly used radio-pharmaceutical in PRRT is 177Lu-
DOTATATE, consisting of 177Lu coupled to octreotate with the chelator 
DOTA. The treatment is usually divided into fractions of 7.4 GBq given as an 
intravenous infusion during 30 minutes (76-80). To prevent the uptake in the 
kidneys, infusions of the positively charged amino acids lysine and arginine 
are administered concomitantly, starting 30 minutes before the 177Lu-
DOTATATE infusion is initiated (81). Patients recover quickly after treatment 
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and the hospital stay surrounding therapy is mainly indicated for radiation 
protection reasons. 
After treatment patients are monitored with blood sampling, to determine the 
renal and haematological impacts. A biokinetic and dosimetric evaluation of 
the radiopharmaceutical is usually performed with repeated planar 
scintigraphy and/or single-photon emission computed tomography (SPECT). 
The treatment fractions are repeated every 6 to 10 weeks, allowing for the 
recovery of bone marrow and kidneys between fractions. Since renal side 
effects constitute one of the main clinical concerns, the renal uptake often 
determines how much radiation that can be delivered. In a commonly used 
clinical protocol for PRRT, fractions are repeated up to 4 times, unless the renal 
dose limit of 23-28 Gy is exceeded (80, 82). 
 
Effect of 177Lu-DOTATATE 
Peptide receptor radionuclide radiotherapy is a palliative treatment often 
resulting in halted tumour progression or shrinkage of the tumour, but very 
rarely cure. The tumour response of 177Lu-DOTATATE is highly variable with 
objective response rates between 24 and 36%, and progressive disease between 
3 and 20% (76, 83-85). Different NETs seem to respond differently to the 
treatment. Other important effects are symptom relief and improvement of 
quality of life for patients (84, 86). 
In animal studies complete remission of tumour has been demonstrated with 
escalated doses (87), but in humans the side effects are dose-limiting (84). 
Clinical dose-response investigating studies are few, but in a recently 
published study by Garske et al. a renal dose-driven protocol was proposed 
(85). A correlation was described between radiological tumour response and 
absorbed dose to the kidneys, indicating a better treatment effect when a high 
kidney dose was achieved. It has also been demonstrated that 177Lu-
DOTATATE improves long-term outcome. In a large prospective study 
(NETTER-1) 177Lu-DOTATATE was superior compared to high-dose SSA 
when evaluating radiological response rate, PFS and possibly OS (88). 
 
Anna-Karin Elf 
13 
Side effects of 177Lu-DOTATATE 
Treatment with 177Lu-DOTATATE is generally well tolerated by patients, with 
only mild side effects associated with the treatment administration. The most 
commonly described side effects are nausea and abdominal discomfort. 
A more serious side effect is the renal radiotoxicity (77, 80). The 
radiopharmaceutical is eliminated by renal excretion which involves 
glomerular filtration, but due to tubular reabsorption a renal retention of the 
radioactivity occurs. Renal radiotoxicity was more pronounced before 
concomitant amino acid infusion became a clinical praxis (89), but decreased 
renal function after PRRT is still one of the major clinical concerns. The initial 
dose limit to the kidneys was based on the extrapolation from obtained toxicity 
with external irradiation (90) and was set to 23 Gy. Since then, the absorbed 
dose levels and the toxicity profile have been investigated and different 
maximum levels to avoid decreased renal function have been advocated. Bodei 
et al. proposed that 28 Gy seems to be a safe biological effective dose (BED) 
for patients with risk factors for renal impairment (co-morbidities such as 
hypertension and diabetes), and 40 Gy for patients without risk factors (71). 
Haematological toxicity is another important side effect of PRRT. A transient 
decrease in platelet and leukocyte count is often observed, but patients usually 
recover between treatment fractions (78). Occasionally, a persistent bone 
marrow depression has to be managed by extended intervals between fractions, 
but in some patients the haematological toxicity is more severe (77). A 
correlation between an inferior renal function and increased haematological 
toxicity has been demonstrated, which has partly been explained by the 
prolonged circulation time of 177Lu-DOTATATE due to the decreased renal 
excretion (80, 91). 
 
RADIOBIOLOGY ASPECTS 
Radiotherapy has since long been an important and integrated part of many 
cancer treatment regimes and aims predominantly to induce DNA damage in 
tumour cells resulting in halted proliferation or cell death. 
The radiosensitivity of a cell varies depending on cell cycle phase, where cells 
in mitotic (M) and G2 phases are more radiosensitive than cells in non-mitotic 
phases G0/G1 and S (Fig. 3). Rapidly dividing tumour cells have less time to 
repair DNA damages, making them more susceptible to the damaging effects 
of radiation. Furthermore, many cancer cells have defective DNA repair 
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systems, and a failure of DNA repair or to halt mitosis despite unrepaired DNA 
lead to cell death (92, 93). However, most NETs are proliferating slowly, much 
slower than e.g. the intestinal mucosa, implying a relative radioresistance. 
 
Figure 3. Phases of the cell cycle. M and G2 phases are more sensitive to 
radiation than G1 and S phases. Illustration by Simon Caulton. 
Ionizing radiation can induce cellular death in several ways (94). Apoptosis, 
necrosis, mitotic catastrophe and cellular senescence are common ways of 
cellular death induced by irradiation. The DNA is the main target of radiation 
therapy. The ionizing radiation damages DNA directly (direct action causing 
strand breaks, base damages and cross-links) and ionizes water molecules, 
producing highly reactive free radicals (OH•, H•, e-aq), which damage DNA 
indirectly via biomolecular ionization. A radiation dose of 1 Gy is considered 
to induce approximately 1000 single strand breaks, 40 double strand breaks, 
3000 base damages and 100 000 ionizations in a cell (95). 
Upon DNA damage, different DNA repair mechanisms are activated 
depending on type of damage. To initiate DNA repair, the DNA damage must 
be recognized by the cell. One of the best studied proteins with DNA-damage 
scanning activity is the nuclear enzyme poly(ADP-ribose) polymerase 1 
(PARP-1) (96). At a site of DNA-strand breakage, PARP-1 is activated and 
catalyses the transfer of ADP-ribose moieties from its substrate nicotinamide 
adenine dinucleotide (NAD+) to nuclear proteins and histones. By modifying 
the architectural proteins close to the DNA breaks, the condensed chromatin 
structures are opened, making them more accessible to DNA repair enzymes 
(97). This beneficial effect of PARP-1 can also be deleterious for the cell. 
NAD+ serves not only as a substrate during ADP ribosylation, but is also a 
coenzyme involved in several redox reactions, including adenosine 
triphosphate (ATP) generation. Thus, after massive DNA damage the 
increased PARP-1 mediated NAD+ consumption can lead to depletion of ATP 
energy stores and cellular death (96). 
Anna-Karin Elf 
15 
NAD+ salvage pathway 
However, NAD+ is normally resynthesized via the NAD+ salvage pathway, 
which under normal circumstances ensures sufficient intracellular levels of 
NAD+. The NAD+ salvage pathway (Fig. 4) involves a few enzymes, of which 
nicotinamide phosphoribosyl transferase (NAMPT) is considered rate-limiting 
(96). The pyridyl cyanoguanidine GMX1778 has been demonstrated to inhibit 
NAMPT and induce cell death by depleting intracellular NAD+ stores (98). 
GMX1778, formerly known as CHS828, has also been used as an anti-tumour 
treatment in animal studies (99). Furthermore, NAMPT inhibition has been 
suggested as a radiosensitization strategy (100). 
 
Figure 4. NAD+ salvage pathway. Hypothetical model of radiosensitizing 
effects of NAMPT inhibitor GMX1778. NAMPT inhibition leads to NAD+ 
depletion. Since NAD+ is a co-enzyme in ATP generation, NAD+ 
depletion can result in loss of energy stores and thereby cell death. NAD+ 
= nicotinamide adenine dinucleotide, Nam = nicotinamide, NMN = 
nicotinamide mononucleotide, NAMPT = Nicotinamide phosphoribosyl 
transferase, NMNAT = NMN adenyl transferase, PARP = poly(ADP-
ribose) polymerase. Adapted from Watson et al. (98). 
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Radiosensitization 
PRRT of NET is usually administered as a monotherapy in a palliative setting, 
the dose chosen to avoid severe side effects. However, the efficacy of treatment 
can be modulated by either making the tumour cells more radiosensitive 
(radiosensitization) or the normal tissues less radiosensitive (radioprotection), 
and thereby widening the therapeutic window of PRRT. As previously 
described, parallel infusions of amino acids are given for radioprotective 
reasons. As a way of increasing the tumoricidal effect, PRRT has been 
combined with chemotherapy (101-104). Though in a true meaning, a 
radiosensitizer has a mechanism of action that is synergistic with the cytotoxic 
radiation and is relatively nontoxic in itself, acting only to potentiate the 
radiation toxicity. 
 
EVALUATION OF TREATMENT RESPONSE 
The evaluation of treatment is based on symptoms, biochemistry and 
morphology. In SI-NETs, symptomatic improvement can be measured as less 
frequency of diarrhoea or flushing episodes. Biochemical tumour markers are 
often monitored and the levels are supposedly reflecting the volume of 
remaining tumour tissue (105). A decrease in chromogranin A (CgA) has in 
some studies been suggested as a predictive marker for morphological 
response (106), while others claim the opposite (107). Further, there are several 
pitfalls when using biomarkers as treatment response evaluation (108, 109). 
Use of proton pump inhibitors elevate both chromogranin A and gastrin, and 
several foods and drugs affect the level of 5-HIAA in urine. Hence, awareness 
and caution must be used when interpreting biomarkers. 
Imaging modalities, e.g. CT and MRI, are possibly more objective and 
repeatable evaluative instruments. 
 
RECIST criteria 
Cross-sectional morphological imaging by CT and MRI is the mainstay for 
surveillance and detection of recurrent disease in NETs. The tumour extent is 
quantified by measuring the diameter of the tumour lesions. This is clinically 
easily applied and there are different guidelines or rules on how to interpret the 
radiological findings. A widely accepted set of rules is the RECIST criteria 
(110). In RECIST, target lesions are identified in the obtained images. These 
are tumour lesions with a diameter of at least 10 mm, or a lymph node tumour 
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where the short axis measures at least 15 mm. Bone lesions are not regarded 
as target lesions and can thus not be used. All measurable lesions up to 10 
lesions in total (maximum 5 organs, up to 2 lesions per organ) are recorded. 
The sum of their longest diameter (LD) is then used in evaluation of treatment 
response. Target lesions should also be selected for their suitability for accurate 
repeated measurements, i.e. all lesions should be assessable in all images used. 
Size change of tumour lesions is then established as: 
 
 
Complete Response (CR): Disappearance of all target lesions 
Partial Response (PR): At least a 30% decrease in the sum of the LD of 
target lesions, compared to the baseline sum LD 
Progressive Disease (PD): The appearance of one or more new lesions or at 
least a 20% increase in the sum of the LD of target lesions, compared to the 
smallest sum LD recorded since the treatment started 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum LD 
since the treatment started 
 
CR and PR are together often referred to as objective response. This 
assessment of treatment response is simple and robust, but demands a 
substantial tumour shrinkage to show an objective response. Treatments can 
result in necrosis and swelling, thus no decreased tumour size can be detected. 
Also, NETs are generally slow-growing and it can take a long time to detect a 
change in tumour size. Therefore, it has been debated whether this 
morphological evaluation is appropriate for assessment of NETs (111, 112). 
 
Diffusion weighted imaging 
Diffusion weighted imaging (DWI) is a functional technique applied in MRI. 
It visualizes changes in diffusion of water molecules in tissue, reflecting the 
micro-environment (111, 113). The change in diffusion can be detected after 
anti-tumoral treatment, which leads to oedema in the tumour and disruption of 
cell membranes. This affects the ability for water molecules to move freely 
intra- and extracellularly, i.e. diffusion (Fig. 5). 
Targeted radiotherapy of metastatic NET 
18 
The amount of diffusion-sensitization applied is indicated by the b-value, 
which is dependent in a specific mathematical way on the magnetic gradient 
amplitude, the duration of the gradient and the time between the two gradients 
applied in the sequence. The higher the b-value, the more sensitive an image 
is to the effect of diffusion. The diffusion can be quantified in a more precise 
way by the apparent diffusion coefficient (ADC). ADC is calculated by 
performing imaging using two or more b-values. At high b-values (> 100 
s/mm2) the signal attenuation primarily depends on molecular diffusion, while 
at low b-values (< 100 s/mm2) perfusion (capillary blood flow) leads to 
additional signal attenuation. This means that ADC(0-800) is sensitive to 
diffusion as well as to microperfusion, while ADC(120-800) is sensitive to 
diffusion exclusively. 
 
 
 
 
 
 
Figure 5. Diffusion in the cellular microenvironment. Diffusion, 
depicted by lines, varies depending on cell density, amount of extra-
cellular space and the integrity of cellular membranes. Illustration by V. 
Johanson 
Studies on tumour response evaluation with DWI have demonstrated that a 
functional response is often earlier detectable than an anatomical (46, 114). 
Theoretically the initial treatment response affects tumour viability rather than 
size (115). Post-treatment evaluation with DWI has also been studied in NETs 
(116-118). 
There are currently no uniform protocols on how to assess NET treatment 
response with DWI, but this functional method seems to be an important new 
tool for tumour evaluation (118-120). 
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Dosimetry of 177Lu-DOTATATE 
Dosimetry is the way to measure the absorbed dose in tissue, which is used to 
predict and determine the effects of radiation. The absorbed dose is defined as 
the amount of energy deposited in a tissue by radiation per unit mass of the 
tissue and has the unit Gray (Gy = Joule/kg). When using gamma-emitting 
radionuclides, the radiation can be detected and quantified by a gamma camera 
with planar or SPECT imaging (Fig. 6). After the radionuclide injection, a 
biokinetic estimation of the decay in tissue is performed by repeated imaging, 
enabling the calculation of the cumulative activity (121). Frequent imaging is 
needed to make as precise estimates of the uptake and elimination of the 
activity as possible, and both early and late time points are necessary to capture 
the dynamics.  
Calculation of the cumulative activity of the radiopharmaceutical is 
complicated, especially in tumours located in the liver, since the tumours are 
sometimes small and the normal liver tissue has a physiological uptake of 
activity. When using planar images, the conjugate view method is the most 
commonly used model to quantify the activity (122). In planar gamma camera 
images, a region of interest (ROI) is drawn around the organ or tumour to be 
measured. The counts recorded are corrected for background counts, using a 
background ROI located in close proximity (123, 124). 
After acquisition of the activity at the different time points, a time-activity 
curve can be fitted and the accumulated activity is calculated from the area 
under the curve. In a low-resolution CT the volume of the organ or tumour is 
estimated. The total electron energy emitted per decay of the radionuclide is 
obtained, and thereby the absorbed dose can be calculated (125). SPECT 
imaging at one time point (usually at 24h) can be used as a complement to 
planar images. The activity of the measured organ or tumour is then obtained 
directly, and the time-activity curve is adjusted accordingly for a correct 
activity concentration estimation (126). Calculation of the activity can also be 
performed by using exclusively SPECT imaging (127). 
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Figure 6. SPECT/CT (A) and anterior-posterior planar (B) images after 
177Lu-DOTATATE treatment. Target lesions from diagnostic CT images 
are identified and regions of interest are drawn around the lesions, after 
which activity counts are recorded. When using planar images, the 
background activity is subtracted to obtain the activity of the lesion. 
  
A 
B 
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Dosimetry of 90Yttrium 
There are two different microspheres used for 90Y radioembolization: resin and 
glass. The spheres differ size and activity amount, which leads to that the 
treatment volumes differ and thereby the embolic effect (128). The resin 
spheres are the most commonly used and approximately 50 million spheres are 
delivered when the whole liver is treated. 
Before administration an individual dosimetry is performed. There are three 
methods to calculate the correct treatment activity and the most frequently used 
is the Body Surface Area (BSA) method, which relies on empiric data and 
mainly takes the patient size into account. A somewhat more sophisticated 
method is the partition model, where a specific equation is used, which regards 
the tumour/normal tissue ratio of the liver and the decided maximum dose to 
the normal liver tissue. Also, the lung shunting component is considered, using 
the preceding scintigraphy with 99mTc labelled macro-aggregated albumin 
(99mTcMAA). If the shunting fraction is 10-20% the planned dose is adjusted, 
and if it exceeds 20%, treatment is not an option due to too high risks for side 
effects. The partition model is considered to be a better option for dosimetry, 
since it more reliably avoids exposing the normal tissue for high doses of 
radiation, which could induce radiotoxic side effects, e.g. radiation 
pneumonitis, radiation induced liver disease (RILD) and radiation ulcer (129). 
After the treatment, the biodistribution of the microspheres is verified by 
imaging. Despite that 90Y is a pure ß emitter, gamma camera measurements 
can be done. The emitted ß particles generate Bremsstrahlung (photons) and 
due to the high activity concentration in the liver these can be detected by a 
gamma camera (130). The activity distribution is therefore visualized by a 
SPECT after treatment (Fig. 7A). However, depending on the physical 
characteristics of Bremsstrahlung, the images can be of poor quality, why they 
are often complemented with a PET (Fig. 7B). This is possible due to a 
combination of the occasional positron emission in 90Y decay and the relatively 
high concentration of radioactivity in radioembolization (131). 
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Figure 7. Imaging after 90Y radioembolization, transaxial (left) and 
coronary (right) views. A) Bremsstrahlung imaging with SPECT/CT, 
showing the selective activity uptake in the liver. B) PET/CT images give 
higher resolution. The yellow areas depict tumour tissue. 
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AIMS OF THE THESIS 
The use of targeted radionuclide therapy in metastasized NET has increased 
during the last decade. Treatments are resource demanding and costly with 
potentially toxic side effects and a highly variable treatment response. The 
general aims of the thesis were therefore to contribute to a better understanding 
of treatment with 177Lu-DOTATATE and 90Y hepatic microspheres and 
thereby improve selection of patients who would benefit from these treatments. 
Specific aims were  
• To identify prognostic factors for long-term outcome and 
toxicity, from a consecutive patient series treated with 177Lu-
DOTATATE 
 
• To investigate if the absorbed tumour dose at 177Lu-
DOTATATE treatment can predict tumour shrinkage 
 
• To investigate if the immunohistochemical expression of 
SSTR2 can predict outcome after PRRT 
 
• To explore the radiosensitizing effect of the NAMPT 
inhibitor GMX1778 in SI-NETs 
 
• To compare treatment response and toxicity of hepatic artery 
embolization (HAE) and radioembolization (RE) in SI-
NETs 
 
• To investigate if DWI-MRI can be an early predictor of 
treatment response after embolization of SI-NET hepatic 
metastases 
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MATERIALS AND METHODS 
PAPER I - STUDY DESIGN AND PATIENTS 
This is a clinical retrospective study on all patients treated with 177Lu-
DOTATATE at Sahlgrenska University hospital, Gothenburg, since the 
treatment was initiated in 2006 until 2011. All patients had tumours with an 
uptake on somatostatin scintigraphy (Octreoscan®) exceeding physiological 
liver uptake. Patient characteristics and indication for treatment are shown in 
Table 3. 
Biochemical response and radiological response according to RECIST 1.1 
(110) were analysed. Best morphological response (BR) was also calculated 
on a lesion-by-lesion basis. To calculate BR the relative change in longest 
diameter of each tumour, from baseline until the time of the smallest 
measurement of the same diameter, was analysed. 
Long-term treatment outcome including progression-free survival (PFS) and 
overall survival (OS) was obtained. Long-term renal and haematological 
toxicities were evaluated by glomerular filtration rate (GFR) and blood cell 
count, respectively. Toxicities were graded according to common toxic criteria 
for adverse events (CTCAE v. 4.0). Renal and tumour dosimetry were 
performed. 
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 SI-NET Pan-NET Rectal NET 
Kidney 
NET 
Presacral 
carcinoid 
Lung 
carcinoid Neuroblastoma Total 
n 31 11 4 2 1 1 1 51 
Median age 63 54 65 38 41 64 38 59 
Male sex 18 5 3 2 1 1 1 31 
Tumor 
grade         
1 19 2  2 1   24 
2 5 7 3     15 
3  1 1    1 3 
Not 
evaluated 7 1    1  9 
Indication         
Progressive 
disease 21 8 4 1  1  35 
Inoperable 
disease 6 1  1 1  1 10 
Adjuvant 
therapy 1       1 
Neoadjuvant 
therapy  1      1 
Excessive 
symptoms 3 1      4 
 
Table 3. Patient, tumour and treatment characteristics. Tumour grade according to 
WHO classification (4th edition). 
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177Lu-DOTATATE treatment and dosimetry 
An average amount of 7.5 GBq (range 3.5 – 8.2 GBq) 177Lu-DOTATATE was 
given as a 30-min intravenous infusion co-administered with kidney protective 
amino acids (2.5 % lysine and 2.5 % arginine in 1 L of 0.9 % NaCl) for 4 hours. 
The treatments were repeated approximately every 8 weeks (range 6 – 10 
weeks). All but 3 patients were planned for 4 treatments, but 23 patients 
discontinued therapy for different reasons: risk of exceeding renal dose limit 
(n=11), persistent haematological toxicity (n=5), low performance status 
(n=2), rapid disease progression and death (n=4) or own choice (n=1). Four 
patients received 5 treatments. 
Planar gamma camera images were obtained at 1.5, 24, 48 and 168 h after 
177Lu-DOTATATE treatment. These images, combined with a single photon 
emission computed tomography and a low-resolution CT (SPECT/CT) at 24 h 
were used for dosimetry. 
Renal dosimetry was performed using the conjugate view method (122). The 
effective attenuation coefficient, sensitivity, anterior and posterior counts from 
the planar images were obtained. The counts in the anterior and posterior 
images in a region of interest (ROI) surrounding the kidney were recorded and 
the counts in a background ROI located caudal to the kidney ROI were 
subtracted. Patient and kidney thickness were determined in the CT. A 
monoexponential curve fit was applied to the time-activity data and the 
accumulated activity was calculated. 
Tumour dosimetry was performed on the target lesions used in the RECIST 
evaluation. Activity concentration was measured in the SPECT/CT images, 
which were reconstructed with our recently developed Monte Carlo based 
ordered subset expectation maximum reconstruction method SARec (132). 
The background ROI and the tumour ROI were drawn in geometrical mean 
images of the planar anterior and posterior images. The conjugate view method 
was applied and a biexponential time-activity curve was fitted and matched to 
the activity concentration from the SPECT/CT. 
The cumulative absorbed dose to the tumours until date of best response (BR) 
was also calculated. The relationship between the cumulative absorbed dose 
and BR was evaluated using linear regression analysis. 
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Figure 8. Images used for tumour dosimetry. A-C) SPECT/CT images 
where tumour region of interest (ROI) was drawn around para-aortal 
tumour lesion. D) Diagnostic CT where target lesions were identified. E) 
Planar images anterior-posterior view, where tumour and background 
ROIs are indicated. 
Figure 9. Activity calculation by a biexponential curve fitted from 
activity measurements in repeated planar and SPECT images. P.i. = 
post-injection of PRRT. 
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PAPER II – STUDY DESIGN AND PATIENTS 
In this study we wanted to explore the relationship between 
immunohistochemical (IHC) expression of SSTR2 and long-term outcome in 
177Lu-DOTATATE treated patients. A previously assembled tissue microarray 
(TMA) of tumour tissue from 412 patients, who were surgically resected for 
SI-NET at Sahlgrenska University hospital, Gothenburg during 1986-2013, 
was used for IHC analysis (133). Two subgroups of patients were identified: 
Cohort A (n=44) included all patients also treated with 177Lu-DOTATATE at 
SU until 2016 and cohort B (n=34) included all patients with specimen from 3 
different locations (primary tumour, lymph node and liver metastasis). Cohort 
B was obtained as a control group for consistency regarding SSTR2 scoring 
between lesions at different sites. Survival analysis was performed and clinical 
data regarding treatments was obtained for both cohorts. Two patients in 
Cohort A (one from each subgroup) were excluded from survival analyses due 
to that they had rapid disease progression and died before completing PRRT. 
 
Immunohistochemistry and scoring 
All TMA blocks were immunohistochemically (IHC) stained for expression of 
SSTR2, Ki-67, chromogranin A and synaptophysin. Antibodies used were: 
anti-SSTR2a (clone UMB1; cat no. 134152 [Abcam]), anti-chromogranin A 
(MAB319; Chemicon), anti-synaptophysin (SY38, M0776; Dako) and anti-
Ki67 (MIB1; Dako).  
SSTR2 expression was scored semi-quantitatively into one of 4 categories (0-
3), depending on level of expression (Fig. 10). The scoring system was based 
on the immunoreactive scoring method previously described by Specht et al 
(134). Briefly, using all specimen on the TMA blocks, a score for staining 
intensity between 0-3 was determined. A scoring (0-4) for percentage stained 
cells was also performed. These two scores were then multiplied for a 
combined score of 0-12, which was then divided into separate groups (score 0-
1 = group 0, score 2-3= group 1, score 4-8= group 2 and score 9-12 = group 3. 
When we applied this method to cohort A and B samples a consistently 
homogenous expression pattern was found, with over 80% stained cells in all 
samples with the exception of 4 negative samples (i.e. score 0). Therefore, 
staining intensity was the primary determinant for final score. 
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Figure 10. SSTR2 scoring. Homogenous expression pattern of cells, 
therefore staining intensity was the determinant for SSTR2 score. 
Activity concentration in tumours 
In 177Lu-DOTATATE treated patients (cohort A) an estimation of the uptake 
of radionuclide was done by measuring the activity concentration in SPECT 
images, obtained 24h after treatment. Tumours were identified by visual 
inspection of images, and up to 3 tumours containing the highest maximum 
voxel values in each patient were chosen for assessment. Activity 
concentration calculation was done by dividing the maximum voxel value with 
SPECT sensitivity and mass of the tissue represented by the voxel. Then, the 
activity was divides by the amount of injected activity, giving the specific 
activity concentration. 
 
PAPER III – SUBJECTS AND METHODS 
Paper III is an experimental study on female BALB/c nude mice xenografted 
with tumours derived from the cell line GOT1, which is a human SI-NET cell 
line. The xenografting procedure is previously described (135). Tumour-
bearing animals were divided into 6 treatment groups (Table 4). 
Group Treatment 
1 (n=6) Controls 
2 (n=10) 177Lu-DOTATATE (7.5 MBq) 
3 (n=7) GMX1778 x 1 (100mg/kg) 
4 (n=5) GMX1778 x 3 (3 weekly doses of 100mg/kg) 
5 (n=6) 177Lu-DOTATATE (7.5 MBq) + GMX1778 x 1 (100mg/kg) 
6 (n=5) 177Lu-DOTATATE (7.5 MBq) + GMX1778 x 3 (100mg/kg/w) 
 
Table 4. Groups and treatments in study III. 
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177Lu-DOTATATE, with a specific activity of 30MBq/µg, was administered 
by injection into the tail vein. 
GMX1778 (N-(6-chlorophenoxyhexyl)-N'-cyano-N"-4-pyridylguanidine) 
was formulated as a 20mg/mL suspension in 2% carboxymethyl cellulose in 
0.9% saline. The drug was administered by oral gavage either as single dose 
or repeated weekly for 3 doses. In the groups with combined therapy, 
GMX1778 was given 1h after 177Lu-DOTATATE. 
The animals were monitored regularly with measurements of weight and 
tumour size. Tumour volumes were calculated by assuming spheroid shapes 
(𝑉 = 4𝜋𝑟&	𝑟(	𝑟) ∕ 3). The animals were followed up to 17 weeks and killed 
when tumour weight exceeded 10% of body weight or if body weight 
decreased more than 10%. 
For biochemical evaluation of NAD+, in vitro studies were performed. GOT1 
cells were cultured as previously described (99) and divided into 4 treatment 
groups (Table 5). After incubation for 1h with GMX1778 at 10 or 0 nM, cells 
were irradiated with 1 or 0 Gy.  Cells were harvested at 1, 5 and 14h after 
irradiation. Cells were pelleted and analysed for NAD+ by liquid 
chromatography-mass spectrometry. 
Group Treatment 
1 control 
2 GMX1778 (10 nM) 
3 external irradiation (1 Gy) 
4 GMX1778 (10 nM) + external radiation (1 Gy) 
 
Table 5. Treatment groups in cultured GOT1 cells. 
 
PAPER IV – PATIENTS AND METHODS 
This is a prospective study on patients with multiple hepatic SI-NET 
metastases not accessible to curative resection or ablation. All patients had 
previous resection of all extra-hepatic tumours and were then randomized to 
either hepatic artery embolization (HAE) or radioembolization (RE) with 90Y-
microspheres. Radiological and biochemical tumour marker evaluations were 
performed. Haematological and liver-specific toxicity was monitored weekly 
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during the first month and after 3 and 6 months. Patient and tumour 
characteristics in Table 6.  
Embolization procedures 
The work-up preceding radioembolization (RE) included angiography with 
protective coiling of the gastroduodenal artery and determination of shunting 
between liver and lung circulation via scintigraphy with 99mTc-MAA in a 
standardized manner (136). RE was performed by depositing 90Y resin 
microspheres (SIR-spheres®, delivered by SIRTex) (diameter 20-60 µm) in 
the common hepatic artery with activity calculation using the partition model 
(129). 
Hepatic artery embolization (HAE) was performed using polyvinyl alcohol 
particles (diameter 45-150 µm) into the right or left hepatic artery until stasis 
was achieved. The right lobe was embolized first, repeating the procedure in 
the left lobe after median 6 (range 5-10) weeks. 
 
Imaging and analysis 
Magnetic resonance imaging (MRI) including T1 and T2 weighted scans and 
diffusion weighted imaging (DWI) scan with multiple b-values were 
performed at baseline and 1, 3 and 6 months after treatment. A T1-weighted 
dynamic contrast-enhanced sequence in late arterial and portal venous phases 
was added in examinations at baseline, 3 and 6 months. 
Up to 5 liver metastases were analysed per patient. Multiple regions of interest 
(ROI) were drawn around the tumours to include the whole tumour volume on 
the DWI images. The relative ADC values were calculated and data from 
baseline and 1-month images were used for comparison. 
Response evaluation was performed according to RECIST 1.1 (Eisenhauer 
2009) using the two best measurable and representative lesions in each patient. 
The response was also determined on a lesion-by-lesion basis, by calculating 
the change in the longest diameter (LD) in all assessable tumours. 
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All patients      
(n= 11) 
RE treatment    
(n= 6) 
HAE treatment 
(n=5) 
Age, years, median 
(range) 67 (40-79) 66.5 (40-79) 67 (51-79) 
Male sex (%) 3 (27) 2 (33) 1 (20) 
Number of lesions 
analysed, median (range) 4 (1-5) 5 (2-5) 3 (1-5) 
Median LD, mm (range) 20.3 (13-55) 20.3 (13-50) 19.9 (13-55) 
Median sum of LD of 
metastases analysed, mm 
(range) 
77 (30-170) 89 (35-170) 74 (30-170) 
Median baseline        
ADC (120-800),                 
10-3mm2/s (range) 
0.73 (0.5-1.3) 0.78 (0.5-1.3) 0.68 (0.5-1.0) 
Primary tumour, grade 1 
(Ki-67 <3%) (n) 7 5 2 
Primary tumour, grade 2 
(Ki-67 3-20%) (n) 4 1 3 
Median dU-5HIAA 
(µmol/24h) (range) 110 (21-270) 97 (54-130) 110 (21-270) 
Median S-CgA (µg/L) 
(range) 231 (81-1890) 162 (81-470) 384 (115-1890) 
 
Table 6. Baseline clinical and tumour characteristics. RE = radioembolization, 
HAE = hepatic artery embolization, LD = longest diameter, ADC = apparent 
diffusion coefficient, dU-5HIAA and CgA = tumour biomarkers. 
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ETHICAL CONSIDERATIONS 
Studies I, II and IV were approved by the Regional Medical Ethics Committee 
in Gothenburg. Diary numbers are 833-12, 373-05 and 540-13, respectively. 
Study III was approved by the Ethical Committee for animal research at the 
University of Gothenburg. Diary number 341-2005. 
 
STATISTICS 
Kaplan Meier curves were used for PFS and OS in study I-II and for time to 
tumour progression in study III. Mantel-Cox log-rank test was used for 
comparison of curves.  
For dosimetry relationships in paper I t-test and linear regression were used. 
For all statistical analyses of data generated from IHC scoring in paper II, non-
parametric tests were used. For comparisons between two groups Mann-
Whitney U test was used. For comparisons between 3 or more groups Kruskal-
Wallis one-way ANOVA was used. Tukey’s multiple comparison was applied 
when needed for correction of p values. Prizm software (version 7.0) and Excel 
(version 16.15) were used for statistical analyses. 
In paper IV radiological response rates were estimated by binomial proportions 
and compared with Fischer´s exact test, using MedCalc statistics package 
(MedCalc Software, Ostend, Belgium). Linear mixed models were used to test 
for difference between changes in ADC parameters and for linear correlation 
between ADC parameters and change in tumour size. These calculations were 
performed in MATLAB 2016b (MathWorks Inc, Natick, MA, USA). Mann-
Whitney U test or Wilcoxon signed-rank test were used for comparing 
differences in continuous variables.  
In all tests a p value of <0.05 was considered statistically significant. 
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RESULTS 
RETROSPECTIVE STUDY OF 177LU-DOTATATE 
Fifty-one patients received 177Lu-DOTATATE treatment from 2006 to 2011, 
of which 40 were assessable according to RECIST 1.1. Most patients (n = 33; 
83%) had stable disease (SD) as the best response after therapy. One patient 
had CR and 4 had PR, adding up to an objective response rate (CR and PR) of 
13%. Progressive disease (PD) was radiologically verified in 2 patients. 
Subgroup analyses according to diagnoses and tumour grades were performed 
(Fig. 11). The patients with objective response were predominantly found in 
pan-NET and non-SI-NET/non-pan-NET group, while SI-NET patients were 
more likely to have SD as the best response. Patients with G2 tumours were 
objective responders to a larger extent than patients with G1 and G3 tumours. 
 
 
Figure 11. Radiological (RECIST) response per diagnosis (A) and 
tumour grade (B) after 177Lu-DOTATATE. Objective responders were 
mainly found in pan-NET, non-SI-NET/non-pan-NET and G2 subgroups. 
Results are shown as fractions within subgroup. SI-NET=small intestinal 
NET, pan-NET=pancreatic NET, n-SI/n-pan=non-SI-NET/non-pan-NET. 
CR=complete regression, PR=partial regression, SD=stable disease, 
PD=progressive disease, NE=not evaluated. 
Biochemical response could be analysed in 45 patients, revealing an objective 
response (≥50% decrease of, or normalized CgA / 24h U-5HIAA) in 33% 
(n=15) patients. In 18 patients (40%) the tumour markers were changed less 
than 50%, and 8 of the patients did not have elevated levels of tumour markers 
at baseline. Four patients had >50% increased biomarkers despite treatment. 
A B 
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Both biochemical and tumour size evaluations were performed in 18 patients, 
however there was no correlation between these variables (p=0.51). 
 
Tumour dosimetry and response  
In previously selected RECIST target lesions, tumour dosimetry was 
performed. This was possible in 24 patients, who had 1-4 tumours assessable 
in all series of planar scintigraphy and SPECT/CT imaging. Hence, in 52 
tumours the absorbed dose was calculated. The median cumulative absorbed 
dose and specific absorbed dose were 57 Gy (range 10-201) and 2.1 mGy/MBq 
range 0.39-7.5), respectively, however large inter- and intra-patient variability 
was observed (Fig. 12). 
Figure 12. Cumulative absorbed tumour doses and specific absorbed 
tumour doses in 52 tumours in 24 patients. Large inter- and intra-
patient variability was observed. Gy = Gray, Bq = Bequerel. 
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When the relationship between the absorbed tumour dose and the tumour size 
change was investigated, the tumours from one patient were not assessable in 
the diagnostic CT images. This resulted in that analyses were possible for 50 
tumours in 23 patients. A statistically significant correlation was found 
between the median absorbed tumour dose and median tumour (p=0.048) 
(Fig.13). 
 
Figure 13. Dose-response curve between median absorbed tumour dose 
and median best response (tumour diameter shrinkage) in 23 patients. 
R=0.42, p=0.048. 
 
Renal dosimetry and treatments 
Calculation of absorbed renal dose was performed after each treatment to avoid 
exceeding the cumulative kidney dose limit, which was set to 27 Gy. This 
resulted in reduced doses or cancellation of further treatments for 13 patients. 
Initially, for calculation of absorbed renal dose, an estimation of the kidney 
size was performed assuming the shape of an ellipsoid. A later reassessment 
for a more correct kidney size estimation, using kidney segmentation in the 
diagnostic CT images, resulted in generally larger kidney sizes and thus lower 
absorbed renal doses. 
The median cumulative absorbed renal dose was 14.4 Gy (range 4-25.9). The 
relatively low cumulative dose admitted further treatments when the patients 
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had tumour progression. Ten patients received additional PRRT after 1.5 to 5 
years, resulting in a median cumulative absorbed renal dose of 25.8 Gy (range 
16.8-44.3) for these patients. 
 
Long-term outcome 
The patients were followed for 1-127 (median 65) months. Tumour 
progression was determined by radiology or by clinical deterioration. Median 
progression-free survival (PFS) was 45 months (95% CI 29-65 months). Five 
patients received the treatment as salvage therapy, but had a rapid tumour 
progression and died within 10 months (median 2 months). In subgroup 
analyses, no statistically significant differences were seen between diagnoses 
(p = 0.13), but G3 tumours progressed earlier than G1 and G2 tumours (13, 62 
and 45 months, respectively) (p = 0.0001) (Fig 14). 
Median overall survival (OS) was 51 months for all patients (95% CI 37-69 
months). OS was not significantly different between SI-NETs, pan-NETs and 
other tumours (64, 44 and 86 months, respectively) (p = 0.99), but patients 
with G3 tumours had significantly shorter OS than those with G1 and G2 
tumours (18, 74 and 72 months, respectively) (p = 0.0002) (Fig 14). 
 
Figure 14. PFS and OS after first 177Lu-DOTATATE.  G3 patients had 
significantly shorter PFS and OS than G1 and G2 patients (p=0.0001; 
p=0.0002). 
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Toxicity 
The median baseline GFR was 78 mL/min/1.73 m2 (range 44-107) and 5 
patients had a GFR below 50 mL/min/1.73 m2. Evaluation of 30 patients at 17 
months (median, range 5-42) after the first treatment showed a GFR decrease 
of 6.4%. Only one of the patients with low follow-up GFR had a significant 
decrease from 44 to 29 mL/min/1.73 m2 after 2 treatments. Long-term GFR 
was evaluated in 26 patients after median 66 months (range 14-108) after the 
last treatment, and it had decreased by 16.7% to 64 mL/min/1.73 m2 (median, 
range 33-89). 
Haematological toxicity was the reason for cancelling planned treatments in 5 
patients, who developed grade 3 thrombocytopenia (3 patients) and grade 2 
and 3 leukopenia (2 patients). Further one patient, who was previously liver 
transplanted due to NET hepatic metastases, developed grade 3 
thrombocytopenia after the fourth treatment, and had a progressive clinical 
deterioration and died 8 months after the last treatment. Long-term 
haematological assessment was performed in 33 patients at 61 months 
(median; range 11-108) after the last cycle of PRRT. One of the patients who 
suffered from haematological toxicity had completely recovered after 57 
months, but the remaining 4 patients still showed bone marrow impairment. 
Nevertheless, despite an advanced tumour stage, most patients could receive 
all planned treatments without cancellation due to toxicity and no patients 
developed treatment demanding kidney failure. 
 
SSTR2 EXPRESSION STUDY 
For cohort A (PRRT treated patients, n = 44), 95 samples were obtained from 
the tissue microarray (TMA) blocks. The majority of samples (n = 79; 83%) 
had SSTR2 expression scoring 2 or 3. For cohort B (patients with paired 
samples from primary, lymph node and liver metastases), 102 samples were 
obtained, among which 79 (77%) had SSTR2 expression scoring 2 or 3. Only 
4 samples were completely negative for SSTR2 expression (score 0), and these 
were all in cohort A.  
 
SSTR2 expression 
To determine if the SSTR2 expression was consistent in all lesions within a 
patient, all samples from metastases in cohort B were sorted according to 
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SSTR2 expression in corresponding primary tumours. The mean SSTR2 
expression was significantly different in metastases from patients with low 
SSTR2 expression (score 1) in the primary tumour, compared with metastases 
from primary tumours with higher SSTR2 expression (Fig. 15). 
 
 
Figure 15. Samples from cohort B sorted according to SSTR2 score in 
corresponding primary tumour. A consistency between primary tumours 
and metastases was observed. SSTR2 expression is significantly different 
in metastases when sorted according to SSTR2 expression in the primary 
tumours (**=p< 0.01, ***=p<0.001).Boxes show 25th to 75th percentiles, 
whiskers indicate ranges and lines show median.  
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SSTR2 expression and Ki-67 
The patients in cohort A were divided into two groups depending on SSTR 
expression. Eleven patients had at least one lesion with score 0 or 1 and were 
assigned to the group “Low SSTR2”. The remaining patients (“High SSTR2”) 
(n=32) had lesions exclusively scoring 2 or 3. Analysis of tumour proliferation 
rate revealed a significantly lower Ki-67 among patients with low SSTR2 
expressing tumours than in those with high SSTR2 expression (p=0.048) (Fig. 
16). 
 
Figure 16. Maximum Ki-67 in patients from cohort A, grouped 
according to SSTR2 expression. Patients with high SSTR2 had 
significantly higher Ki-67 (p=0.048). Bars show median and 95% CI. 
 
SSTR2 expression and activity concentration 
SSTR2 score was also compared with activity concentration in SPECT at 24h 
after 177Lu-DOTATATE treatment, to estimate the uptake of the radionuclide 
in the tumours. Up to 3 of the lesions with the highest activities were measured 
in each patient. There was a large variability between the 33 patients with 
assessable images (27 with high and 6 with low SSTR2 expressing tumours), 
and the mean activity was 1.51 and 1.91 MBq/g for the High and Low SSTR2 
expressing groups, respectively. Hence, a tendency towards higher activity 
concentration was observed in patients in Low SSTR2 group, however the 
difference was not statistically significant (p = 0.06) (Fig. 17).  
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Figure 17. Activity concentration in patients from cohort A grouped 
according to SSTR2 expression. Patients in Low SSTR2 group had a 
tendency towards higher activity concentration, measured in 2-3 lesions 
in SPECT images at 24h after first 177Lu-DOTATATE treatment (p=0.06). 
Lines show median and 95% CI. 
SSTR2 expression and long-term outcome 
Overall survival (OS) figures were obtained for both cohorts and analysed 
according to SSTR2 expression. No statistically significant difference between 
the groups (p=0.12 for cohort A; p=0.11 for cohort B) (Fig 18). A trend 
towards longer survival was seen in the low SSTR2 group in cohort A, which 
was also strengthened by the complete lack of additional treatment after PRRT 
in this group (data not shown). In contrast, 25% (n=8) of the patients with high 
SSTR2 expressing tumours received additional treatment for NET after PRRT. 
 
Figure 18. OS in cohorts A (A) and B (B), grouped according to SSTR2 
expression. Cohort A: n=42 (Low SSTR2 n=10; High SSTR2 n=32), 
cohort B: n=28 (Low SSTR2 n=11; High SSTR2 n=17). A trend towards 
longer OS was seen for Low SSTR2 groups. in cohort A, however there 
was no statistical difference between groups (Cohort A: p=0.12; Cohort 
B: p=0.11). 
A B 
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RADIOSENSITIZATION STUDY 
Treatment with a semi-efficient dose of 177Lu-DOTATATE (7.5 MBq) resulted 
in mean 45% reduction of tumour volume, compared to baseline. The animals 
receiving GMX1778 (100mg/kg) in a single or 3 weekly doses had a 34% and 
53% mean tumour volume reduction, respectively. When a combination of 
177Lu-DOTATATE and single dose GMX1778 was used, the mean tumour 
reduction was 73% after 3 weeks. Combining 177Lu-DOTATATE and 3 
weekly doses of GMX1778 resulted in a mean tumour volume reduction of 
97% after 4 weeks, and the tumour in one of the animals was completely 
eradicated with no signs of tumour recurrence at the end of the study (after 17 
weeks) (Fig. 19A). 
 
Figure 19. Tumour volume and time to tumour progression of animals. 
Treatment with semi-efficient doses PRRT or GMX1778 resulted in 
modest tumour regression, but combining PRRT with 3 doses GMX1778 
resulted in almost eradicated tumours. No tumours in this group 
progressed, i.e. exceeded volume at the study start. Graph A shows 
median and bars indicate SEM. Ticks indicate censored data. 
Tumour progression was defined as tumour volume exceeding the volume at 
the start of the experiment. A single dose of GMX1778 delayed median time 
to tumour progression marginally (from 3 to 7 days) compared with controls. 
Treatment with 177Lu-DOTATATE or 3 weekly doses of GMX1778 further 
delayed the median time to tumour progression to 35 days. In the combination 
group with 177Lu-DOTATATE and 3 weekly GMX1778 doses 4 of 5 tumours 
eventually had an increased tumour size but none of them showed tumour 
progression, i.e. exceeded the initial volume (Fig 19B). 
 
 
A B 
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Treatment effect on NAD+ levels 
Cultured GOT1 cells were incubated with a low dose of GMX1778 (10 nM) 
or irradiated with 1 Gy, or a combination of both, or received no treatment. 
These doses have a slightly cytotoxic effect, not visible until several days after 
treatment. Irradiation did not affect NAD+ levels, but in the samples with 
GMX1778, the amount of NAD+ was clearly reduced after 5 h and a more 
pronounced effect was seen after 14 h (Fig. 20). This demonstrates that 
GMX1778 affects the NAD+ levels in the tumour cells. 
 
Figure 20. Relative NAD+ levels in cultured GOT1 cells. Cells were 
incubated for up to 14 h with GMX1778 (10 or 0 nM) and were irradiated 
with 1 or 0 Gy at the start of incubation. NAD+ levels decreased distinctly 
in cells treated with GMX1778. 
 
STUDY ON TREATMENT OF HEPATIC 
METASTASES  
Six patients with SI-NET hepatic metastases were randomized to 
radioembolization (RE) and 5 to hepatic artery embolization (HAE). One 
patient could not undergo MRI due to a cardiac pacemaker, and was therefore 
assigned to CT examinations. 
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According to RECIST1.1, all of the HAE treated and none of the RE treated 
patients had PR at 3 months (p=0.002), however all lesions decreased in size. 
At 6 months one of the HAE treated patients had tumour progression and two 
of the RE treated patients had PR, which made the difference between the 
treatment groups statistically insignificant (p=0.24) (Fig. 21). In all patients, 
39 tumour lesions were assessable on a lesion-by-lesion basis. The decrease of 
longest diameter (LD) was significantly larger in HAE treated patients than in 
RE treated patients at both evaluation time points (p<0.001). 
 
Figure 21. RECIST response at 3 and 6 months in target lesions. All 
HAE treated patients and no RE patients had partial response at 3 
months, however at 6 months no statistical difference remained between 
groups. Bars show sum of decrease of 2 tumours in every patient. HAE = 
hepatic artery embolization, RE = radioembolization. 
 
Almost all patients had decreased biochemical tumour markers after 3 and 6 
months and no difference were seen between treated groups. 
Both treatments resulted in low overall toxicity. However, all RE patients but 
one developed moderately elevated alkaline phosphatase (ALP) levels (median 
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2.8 µkat/L) after 3 months, which was significantly higher than HAE treated 
patients (1.4 µkat/L) (p=0.03).  The levels were persistent at 6 months. Median 
hospital stay after HAE was 4 days (range 4-10), which was significantly 
longer than after RE (2 days, range 2-6). 
 
DWI and treatment response 
Ten patients with totally 36 tumours were examined with MRI and diffusion 
weighted imaging (DWI). The baseline ADC(120-800) values were significantly 
negatively correlated with decrease of LD at 6 months, i.e. a low baseline 
ADC(120-800) was associated with a large tumour shrinkage (p<0.01). 
The mean increase of ADC(120-800) at 1 month after treatment seemed higher in 
HAE treated patients (40%) compared with RE treated ones (11%), however 
the difference was not statistically significant (p=0.08). 
There was a statistically significant correlation between the increase of     
ADC0-800 at 1 month and the tumour shrinkage at 3 months (p<0.05) (Fig. 22). 
 
Figure 22. Relative tumour diameter at 3 months of 36 tumours 
compared with ADC increase at 1 month. HAE treated tumours were 
then significantly smaller than RE treated tumours. Blue symbols = 
hepatic artery embolization (HAE), red symbols = radioembolization 
(RE). Figures specify patient number. 
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Figure 23. DWI images from third HAE treated patient. Arrows point at 
tumour lesions in the left and right lobe, respectively. In baseline image 
(A) the low diffusion of tumours is visualized. In image at 1 month (B) the 
lesion in the right lobe has an increased diffusion, visualized by darker 
colour, compared with untreated left lesion. Bottom image (C) at 3 and 
1.5 months after HAE treatment of right and left lobe, respectively. The 
right tumour is hardly visible, and the area around the left tumour is 
affected by treatment. 
A 
Baseline DWI 
(ADC0-800) 
B 
DWI (ADC0-800) at 
1 month after first 
HAE 
C 
DWI (ADC0-800) at 3 
months after first 
HAE 
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DISCUSSION 
 
177Lu-DOTATATE and treatment outcome 
Among the first 51 patients treated with 177Lu-DOTATATE at Sahlgrenska 
University hospital 40 patients were evaluated according to RECIST. Twelve 
per cent of the patients had an objective response (CR + PR). The majority of 
patients (82%) had SD as the best response which adds up to a disease control 
rate of 94%. Almost 70% of the patients had progressive disease before 
treatment, and only 6% (or 14% if including patients with clinical disease 
progression) after treatment, which should be regarded as a good treatment 
response. Most patients had slow growing G1 tumours (57%) mainly 
represented by SI-NET (61% of all patients) but at a disseminated, advanced 
stage not suitable for alternative treatments, e.g. surgery or liver-directed 
therapy. 
Other studies have reported objective response rates higher (76, 83, 84) or 
lower (137) than in this study, but generally lower proportions of SD. 
However, it is difficult to make strict comparisons due to sometimes small 
patient cohorts with heterogeneous NET diagnoses and diverse indications for 
treatment. In this study, the SI-NET proportion was larger than in other studies 
(83, 84) and SI-NETs often have a less distinct treatment response (85, 138, 
139). SI-NET cells often have a lower proliferation rate than other NETs, e.g. 
pan-NETs, thereby the number of tumour cells susceptible for the DNA 
damaging effect of PRRT is theoretically fairly low, making them less 
sensitive to radiation. Hence, this could explain the modest response dynamic 
after PRRT of SI-NETs. 
The median PFS and OS were 45 and 65 months respectively, which is longer 
than other studies (76, 83, 85, 140). However, PFS and OS was not longer for 
SI-NET, which is often reported. Obviously, the OS after treatment is affected 
by the timing of treatment. At the unit for endocrine surgery in Gothenburg, 
the mainstay for first-line treatment of well-differentiated NET has been 
surgery performed as radical as possible(141). Repeated surgery was offered 
for recurring tumours regardless of location, if resectable. Further, patients 
with liver-dominated disease were often treated with liver-directed therapy, 
e.g. HAE or RF ablation. PRRT was the treatment option exclusively for 
advanced, unresectable tumours. 
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Furthermore, the selection of patients is crucial. Present study included a large 
proportion of G1 and G2 tumours in the lower range, which probably affected 
the long-term outcome. In subgroup analyses G1 and G2 tumours had 
significantly longer PFS and OS than G3 tumours, which is well in accordance 
with the known strong prognostic importance of tumour grade (6). The long 
median follow-up time (65 months; range 1-127) in our study ensured reliable 
figures of PFS and OS, hence this avoids too many censored patients in 
analysis of these slow-growing tumours. 
 
Dosimetry and tumour response 
The administered dose of 177Lu-DOTATATE is obviously important for 
treatment outcome (87). However, the treatment can cause radiotoxic 
haematological side effects, e.g. thrombocytopenia, leukopenia and anemia, 
and a risk of decreased renal function. These side effects vary inter-
individually, and the exact dose limit for a safe treatment is not yet clarified. 
Previous studies have shown that haematological side effects and absorbed 
renal dose correlate with pre-treatment renal function (80). However, at low 
glomerular filtration rates (GFR) the absorbed renal doses vary substantially. 
Therefore, the absorbed renal dose, and thus the potential renal radiotoxicity, 
is hard to predict in patients with low GFR (<60 mL/min/1.73 m2). 
In this study the absorbed renal dose limit was set to 27 Gy. Several patients 
(23%) discontinued treatment due to a risk of exceeding this limit, however 
after a correction of kidney size the absorbed doses were adjusted. This 
resulted in a relatively low renal absorbed dose (median 14.4 Gy). In a recently 
published study a renal dose-driven protocol for treatment with 177Lu-
DOTATATE was proposed (85). They demonstrated that an absorbed renal 
dose exceeding 23 Gy (which is the maximum renal dose limit in several 
studies) resulted in an increased probability for objective radiological response 
and prolonged PFS and OS. This seems reasonable, however few studies 
present data on absorbed tumour dose, i.e. the radiotherapy reaching the actual 
target. 
 The absorbed tumour dose is an obvious topic to study in relation to examining 
the efficacy of PRRT, but few studies actually present data on this relationship 
(127, 142). Tumour dosimetry is demanding, since it includes many parameters 
to correct for, e.g. background, scatter, attenuation and sensitivity of the system 
(143). Many tumours are located in the liver where the physiological 
radionuclide uptake can be a disturbance. Also, it is difficult to estimate the 
correct activity in small tumours due to the partial volume effect.  Further, the 
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activity curve reflecting the biokinetics of the radionuclide is an estimation, 
since actual measurements at frequent time points are not feasible in the clinic. 
In this study tumour dosimetry was performed. There were large variations 
between tumours, even when correcting for the administered activity (specific 
absorbed tumour dose). This variation could be explained by differences in 
perfusion or SSTR expression of the tumours, leading to disparities in delivery 
or uptake of the radiopharmaceutical. Alternatively, the proportion and rate of 
internalization of the radiopharmaceutical could differ between tumours (144). 
Nevertheless, a correlation between the median absorbed tumour dose and 
tumour shrinkage was observed. This indicates a PRRT dose-response 
relationship for various NETs, detected even with the relatively low doses used 
in this study. This finding is in accordance with other studies (127, 142), 
however more research is warranted in this scarcely explored field. 
 
SSTR2 expression and clinical outcome in SI-NETS 
In study II the SSTR2 expression in SI-NETs was analysed and only few 
samples lacked or had a low SSTR2 expression. Patients with low SSTR2 
expression in the primary tumour had a significantly lower mean expression in 
metastases than patients with a high SSTR2 expressing primary tumour. 
Hence, a low SSTR2 expression in the primary tumour, implies a risk of low 
SSTR2 expression in the remaining metastases. Therefore, our hypothesis was 
that the clinical outcome of SSTR based therapy, e.g. PRRT, was worse for 
these patients. Surprisingly, these patients needed less additional therapy after 
PRRT than high SSTR2 expressing patients. Furthermore, they had a trend for 
longer OS, even if the difference was not statistically significant. These 
findings are in contrast to other studies who demonstrated a correlation 
between high SSTR2 expression and long OS (145-147). However, in some of 
these studies SSTR2 expression was inversely correlated with Ki-67, and the 
tumour samples were from various NETs, of which some were G3 tumours. 
As previously described, Ki-67 is an independent predictor for long-term 
outcome (13, 83). 
 
SSTR2 expression and SSTR2 imaging 
In this study on well differentiated SI-NETs no positive correlation was seen 
between SSTR2 expression and activity concentration at SPECT 24 h after 
PRRT. Contrastingly, there was a tendency towards a negative correlation. It 
is not unreasonable to expect a positive correlation, since the uptake of the 
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radiopharmaceutical is mediated by SSTR2. Accordingly, a correlation 
between SSTR2 expression and the uptake on 68Ga-DOTATATE-PET has 
been demonstrated in several studies (148-150), however the imaging time 
points differ between the methods, leading to that PET mainly visualizes the 
binding to SSTR and SPECT reflects the biokinetics, e.g. internalization of the 
radiopeptide. Furthermore, in compared studies both low- and high-
proliferative NETs from various origins were included, and a larger proportion 
of the samples had low or no SSTR2 expression. Our findings are in 
accordance with a large study of well-differentiated NETs comprising of 
mainly SI-NET origin, where a correlation between SSTR2 expression and 
SSTR imaging neither could not be seen (145). 
 
Radiosensitization of SI-NET 
Although PRRT is a good treatment option for many patients with metastasized 
NET it is still considered to be a palliative treatment. Further research and 
refinements for this treatment modality is thus needed (151, 152). Different 
strategies for further improvements could include: combination with other 
antitumoral treatments like anti-angiogenesis therapy, oncogenic pathway 
inhibitors or chemotherapy, optimization of the radiopharmaceutical (isotope, 
peptide, chelator) or increasing the dose of the radiolabelled SSA.  
The routine kidney protection measures currently used does not reduce the risk 
of haematological toxicity, but administration of higher doses of PRRT is 
probably possible for some patients under careful dosimetric surveillance (85).  
In most published clinical studies PRRT has been used as a single modality 
treatment for metastasized NET. However, reports on combination treatment, 
e.g. with chemotherapy, are emerging (104, 153-155). These show promising 
results with only modestly increased toxicity.  
NAMPT has been described as an attractive target in treatment of cancer (98). 
Due to frequent DNA damages in tumour cells, there is a continuous need for 
DNA repair in tumour cells. The enzyme PARP-1 plays an important role in 
ADP-ribosylation, which in turn is involved in several DNA repair 
mechanisms (97, 156). This leads to an overactivation of PARP-1 in tumour 
cells, resulting in a high rate of NAD+ turnover and a need for constant 
regeneration via the NAD+ salvage pathway (96). Theoretically, this high 
dependence on constant NAD+ regeneration would make the tumour cells more 
susceptible to NAMPT inhibitors than normal cells (157, 158). It has been used 
in experimental models as single treatment (159) or in combination with 
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radiotherapy (100) or a PARP-1 activator (160), but the few phase I studies 
published did not show any antitumoral effect (161, 162). 
In study III we confirmed our previous findings that semi-efficient doses of 
177Lu-DOTATATE (7.5 MBq) or GMX1778 (100 mg/kg/w) result in 
temporary halted tumour growth or moderate regression in nude mice 
xenografted with the SI-NET cell line GOT1 (87, 99). When combined, the 
same doses of 177Lu-DOTATATE and GMX1778 enhanced the antitumoral 
effect considerably, and resulted in complete or near-complete tumour 
regression in all animals. The mechanism of action of GMX1778 is considered 
to be inhibition of the enzyme NAMPT in the NAD+ salvage pathway (98). 
Our findings in the in vitro experiment support this concept, since GMX1778, 
but not irradiation alone, reduced NAD+ levels significantly. 
Another target in this pathway is PARP-1 and the use of recently developed 
PARP-I inhibitors has been introduced in several cancer protocols (163). The 
rationale for this therapy is that inhibition of PARP-1 leads to a decreased 
repair of radiation-induced single-strand breaks of DNA, yielding an increased 
tumour cell death. A recently published paper demonstrates potentiation of 
177Lu-DOTATATE with a PARP-1 inhibitor in NET cell lines, as an intriguing 
new way of radiosensitization (164). 
 
Liver-directed therapy 
SI-NET patients with stage IV disease often have the main tumour burden 
located in the liver, where the tumours can become large and bulky and cause 
the carcinoid syndrome. In these cases, liver-directed therapy is preferred since 
it spares the rest of the body from side effects, e.g. radiotoxicity after PRRT. 
The mainstay for treating large, widespread hepatic metastases at our unit has 
been HAE (165). The treatment has resulted in satisfactory relief of symptoms, 
tumour regression and possibly prolonged survival for responding patients 
(49). However, some patients are not responsive to treatment and side effects 
related to the induced ischemia can sometimes be cumbersome. We started a 
prospective study with randomization of patients to either HAE or the recently 
introduced RE, which in retrospective studies has yielded similar results as 
HAE, but probably less toxicity and higher tolerability. 
The results in study IV showed that both treatment groups had similar RECIST 
response at 6 months, but HAE treated patients responded earlier than RE 
patients. When analysed lesion-by-lesion, HAE patients had a significantly 
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larger tumour shrinkage at 6 months than RE patients. These findings illustrate 
a difference of the treatments: HAE aims for ischemia and necrosis of the 
metastases. In contrast, the antitumoral effect of RE is radiotoxicity, and 
radiosensitivity is in general correlated with proliferation rate as cell death 
from DNA damage often occurs when the cell with damaged DNA enters 
mitosis. Since the proliferation rate of SI-NETs usually is very low, this can 
theoretically explain the different response dynamics. 
Side effects of both treatments were mild. Apart from one patient who 
developed cholecystitis after HAE (the only not cholecystectomized patient) 
no severe complications were noticed. Notedly, 83% of the RE patients 
developed increased alkaline phosphatase (ALP) levels. These levels were not 
affecting the patients clinically, and other liver enzymes or bilirubin were not 
elevated. The raised ALP levels could be explained by mild radiotoxic effects 
on the normal liver tissue, and has been reported as the most common 
biochemical toxicity in several reports (166, 167). RILD is a potentially lethal 
condition predominantly seen in patients with a previous liver dysfunction or 
damage, e.g. cirrhosis, chemotherapy or hepatitis B or C and is triggered by 
radiotherapy directed against the liver (168, 169). No cases of RILD were seen 
among the study patients. 
 
Evaluation with diffusion-weighted MRI 
In study IV the baseline and 1-month post-treatment DWI images were 
compared with morphological response using MRI. We demonstrated that the 
pretherapeutic diffusion coefficient (ADC120-800) correlated significantly with 
the morphological tumour response (decrease of tumour size) at 6 months. This 
finding corresponds well with other reports both on NET (116) as well as 
colorectal and gastric cancer (170, 171). The biological basis for this finding 
is uncertain, but it has been shown that malignant tumours in general have 
lower ADC values than benign tumours (172, 173), and in a recent review of 
the association between pretreatment ADC and Ki-67 in 12 different tumour 
entities, a negative correlation was shown in most tumour entities including 
NETs (174).These findings probably reflect the cell density, as it has been 
found to inversely correlate with ADC (175). Thus, low ADC values seem to 
correspond with more high-grade tumours, which respond better to 
chemotherapy and radiotherapy. 
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The ADC120-800 increased significantly one month after HAE, but not after RE. 
An increase of ADC is well described in other studies after intra-arterial 
therapy of hepatic NET metastases (117, 176). The morphological response 
after RE was delayed compared to HAE, and it is reasonable to believe that 
this is also the case for ADC changes, although this has not yet been evaluated 
in this study. Theoretically, the observed diversities could depend on the 
differences in mechanism of action of the treatments. Supposedly, HAE 
directly induces ischemia and necrosis, in contrast to RE, where the DNA 
damaging radiation is delivered over time and thereby resulting in a slower cell 
death (177). A post-RE inflammatory response with cellular oedema could also 
be the cause of a hampered ADC increase, as argued in another study (114). 
When the relationship between diffusion and morphology after treatment was 
investigated we found that the ADC increase could not predict the RECIST 
response, i.e. evaluation using only 2 lesions. However, the increase of ADC0-
800 correlated with tumour shrinkage, when analysed on a lesion-by-lesion 
basis, using all 36 lesions. ADC0-800 reflects both the diffusion and pseudo-
diffusion (results from capillary circulation), as opposed to ADC120-800, which 
mainly captures the diffusion. 
In conclusion, our study shows that HAE remains a safe treatment option for 
liver metastases from SI-NET with results comparing very well with the newer 
RE treatment modality. Further studies are needed to establish the definitive 
role of RE and the predictive value of DWI-MRI in these tumours. 
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CONCLUSIONS 
 
• 177Lu-DOTATATE is an effective and tolerable treatment 
option for various NETs at an advanced stage. High tumour 
grade, but not tumour origin, was prognostic for inferior long-
term outcome. 
 
• Tumour dosimetry is feasible and the absorbed tumour dose 
seems to correlate with tumour shrinkage after 177Lu-
DOTATATE treatment. However, large variations within and 
between patients were observed. 
 
• A low expression of SSTR2 in SI-NETs was not a negative 
prognostic factor for long-term outcome after 177Lu-
DOTATATE. Neither was low SSTR2 a negative prognostic 
factor for SI-NET in general (cohort B in study II). Further, a 
low SSTR2 expression was not associated with an inferior 
radionuclide uptake, compared with high expressing tumours. 
 
• GMX1778 can be used as a radiosensitizer with low-dose 
177Lu-DOTATATE in nude mice, xenotransplanted with 
human SI-NET. Both tumour shrinkage and time to tumour 
progression are increased, compared with treatment with only 
one of the drugs. 
 
• Tumour response occurred earlier after HAE compared to RE 
in patients with SI-NET hepatic metastases, but at 6 months 
no significant difference remained. No patients had severe 
side effects. HAE remains a safe option for treatment of 
hepatic metastases from SI-NET. 
 
• A low pre-treatment ADC and a high increase of ADC at 1 
month correlated with a large tumour shrinkage at 6 months, 
after embolization treatment of SI-NET hepatic metastases. 
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FUTURE PERSPECTIVES 
This thesis evokes many questions and challenges to proceed with. Our 
recently closed prospective multicentre study on 177Lu-DOTATATE 
(ILUMINET, EudraCT 2011-000240-16) with regular CT scans and blood 
samplings, will give prerequisites for accurate evaluations. These include 
continued tumour dosimetry and evaluation of its impact on tumour response. 
In the ILUMINET study tumour progression at inclusion was mandatory, 
which will facilitate evaluation of tumour response. Also, as many patients 
seem to tolerate higher absorbed doses of 177Lu-DOTATATE, more treatment 
fractions have been administered in several cases, yielding interesting dose-
response studies to conduct. 
The findings regarding SSTR2 expression were surprising and intriguing. 
Since PRRT is mediated via the SSTRs there should probably exist a 
connection with the SSTR expression. However, this connection possibly 
looks different for SI-NETs than for other tumour entities. The next step is to 
investigate expression of all SSTR subtypes for correlation with anti-tumoral 
effect and long-term outcome after 177Lu-DOTATATE. Also, the remaining 
samples on the TMA should contain further low SSTR2 expressing tumours, 
which will result in a larger material to perform survival analyses in.  
GMX1778 is an interesting substance, that experimentally has resulted in 
positive radiosenstization findings. The hypothesis regarding the place for 
GMX1778 is risen from the same biological pathway in the cell as PARP 
inhibitors, which are recently introduced in NET studies (164, 178). But in 
contrast, the effect of GMX1778 relies on a preserved high level of PARP 
activation and thereby NAD+ consumption. Based on our findings, it would be 
interesting to apply the substance in a clinical setting, which of course is a 
demanding process. 
The prospective study on liver-directed therapies is still recruiting patients, but 
the collected data is a source for many analyses. Further studies on the DWI 
data is planned. The findings of an increased ADC after treatment were 
expected, but there was a difference between HAE and RE. Based on this and 
the fact that the tumours responded later after RE than HAE, the next step is to 
visualize the whole post-treatment ADC dynamic using more time points. 
Hypothetically, the ADC response after RE could be delayed and of a different 
character than the ADC response after HAE. 
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Also, ultrasonographic elastography (ARFI) for evaluation of inflammatory 
response after treatments have been performed, and these data need to be 
analysed. The observed increase of ALP in RE patients could be linked to 
radiation related damages on the vascular endothelium also seen in RILD, but 
to a lesser extent. A platelet activation and aggregation leading to accumulation 
of fibrine and fibroblast proliferation can possibly then be visualized in the 
ARFI investigations (179, 180). 
Finally, quality-of-life questionnaires have been collected and will be analysed 
for differences before and after treatment and between HAE and RE. 
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